Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evandro de Azambuja

Showing results (51-60 of 299) with videos related to

Pageof 30
Sort By:
Expert Opinion on Drug Safety|July 12, 2017
Breast cancer treatment-induced cardiotoxicitySamuel Martel, Christian Maurer, Matteo Lambertini, et al.
Breast (Edinburgh, Scotland)|October 1, 2013
Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapiesAna Catarina Pinto, Felipe Ades, Evandro de Azambuja, et al.
Breast Cancer Research : BCR|February 17, 2009
Are we HER-ting for innovation in neoadjuvant breast cancer trial design?Natasa Snoj, Philippe L Bedard, Evandro de Azambuja, et al.
The Oncologist|January 1, 2008
Review: side effects of approved molecular targeted therapies in solid cancersChristian Widakowich, Gilberto de Castro, Evandro de Azambuja, et al.
Breast Cancer Research and Treatment|January 25, 2022
Implication of body mass index (BMI) on the biological and clinical effects of endocrine therapy plus abemaciclib as neoadjuvant therapy for early breast cancer patientsMaria Alice Franzoi, Matteo Lambertini, Marcello Ceppi, et al.
Expert Review of Anticancer Therapy|December 3, 2008
Jumping higher: is it still possible? The ALTTO trial challengeGianluca Tomasello, Evandro de Azambuja, Phuong Dinh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2010
Sequential or concurrent administration of trastuzumab in early breast cancer? Too early to judgeHatem A Azim, Evandro de Azambuja, Marianne Paesmans, et al.
Anti-Cancer Agents in Medicinal Chemistry|June 10, 2008
HER-2 positive breast cancer: what else beyond trastuzumab-based therapy?Christian Widakowich, Phuong Dinh, Evandro de Azambuja, et al.
Current Opinion in Oncology|September 16, 2011
HER2-overexpressing breast cancer: time for the cure with less chemotherapy?Sherene Loi, Evandro de Azambuja, Lina Pugliano, et al.
Expert Review of Anticancer Therapy|February 24, 2011
Motherhood after breast cancer: searching for la dolce vitaHatem A Azim, Fedro A Peccatori, Evandro de Azambuja, et al.
Pageof 30

Showing results (51-60 of 299) with videos related to

Sort By:
Pageof 30
Expert Opinion on Drug Safety|July 12, 2017
Breast cancer treatment-induced cardiotoxicitySamuel Martel, Christian Maurer, Matteo Lambertini, et al.
Breast (Edinburgh, Scotland)|October 1, 2013
Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapiesAna Catarina Pinto, Felipe Ades, Evandro de Azambuja, et al.
Breast Cancer Research : BCR|February 17, 2009
Are we HER-ting for innovation in neoadjuvant breast cancer trial design?Natasa Snoj, Philippe L Bedard, Evandro de Azambuja, et al.
The Oncologist|January 1, 2008
Review: side effects of approved molecular targeted therapies in solid cancersChristian Widakowich, Gilberto de Castro, Evandro de Azambuja, et al.
Breast Cancer Research and Treatment|January 25, 2022
Implication of body mass index (BMI) on the biological and clinical effects of endocrine therapy plus abemaciclib as neoadjuvant therapy for early breast cancer patientsMaria Alice Franzoi, Matteo Lambertini, Marcello Ceppi, et al.
Expert Review of Anticancer Therapy|December 3, 2008
Jumping higher: is it still possible? The ALTTO trial challengeGianluca Tomasello, Evandro de Azambuja, Phuong Dinh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2010
Sequential or concurrent administration of trastuzumab in early breast cancer? Too early to judgeHatem A Azim, Evandro de Azambuja, Marianne Paesmans, et al.
Anti-Cancer Agents in Medicinal Chemistry|June 10, 2008
HER-2 positive breast cancer: what else beyond trastuzumab-based therapy?Christian Widakowich, Phuong Dinh, Evandro de Azambuja, et al.
Current Opinion in Oncology|September 16, 2011
HER2-overexpressing breast cancer: time for the cure with less chemotherapy?Sherene Loi, Evandro de Azambuja, Lina Pugliano, et al.
Expert Review of Anticancer Therapy|February 24, 2011
Motherhood after breast cancer: searching for la dolce vitaHatem A Azim, Fedro A Peccatori, Evandro de Azambuja, et al.
Pageof 30